Efficacy and safety of zimberelimab (GLS-010) monotherapy in patients with recurrent or metastatic cervical cancer: a multicenter, single-arm, phase II study
Lingfang Xia, Jing Wang, Chunyan Wang, Qingming Zhang, Jianqing Zhu, Qunxian Rao, Huijun Cheng, Zheng Liu, Yongmei Yin, Xiaohong Ai, Kurban Gulina, Hong Zheng, Xiaoyong Luo, Baoping Chang, Li Li, Haiyan Liu, Yunxia Li, Ge Lou, Qi Zhou, Yanling Zhu, Zemin Xiao, Jiandong Tong, Ke Wang, Jie Chen, Xia W · 2023
Read Efficacy and safety of zimberelimab (GLS-010) monotherapy in patients with recurrent or metastatic cervical cancer: a multicenter, single-arm, phase II study by Lingfang Xia, Jing Wang, Chunyan Wang, Qingming Zhang, Jianqing Zhu, Qunxian Rao, Huijun Cheng, Zheng Liu, Yongmei Yin, Xiaohong Ai, Kurban Gulina, Hong Zheng, Xiaoyong Luo, Baoping Chang, Li Li, Haiyan Liu, Yunxia Li, Ge Lou, Qi Zhou, Yanling Zhu, Zemin Xiao, Jiandong Tong, Ke Wang, Jie Chen, Xia W (2023) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-10804044.txt.
Description
Lingfang Xia and co-authors report a phase II trial of zimberelimab, an immune checkpoint drug, for cervical cancer that came back or spread. Patients had already had chemotherapy and still grew worse, so new options were needed. The 2023 study ran at many centers with no control arm.
The trial enrolled 105 women aged 18 to 75 whose tumors tested positive for a marker called PD-L1. Each got the drug by vein, 240 milligrams every two weeks, for up to two years. The main goal was the share of tumors that shrank, judged by a standard rule set and an outside review panel. Safety and side effects were tracked as well.
Catalog record
| CREATOR | Lingfang Xia, Jing Wang, Chunyan Wang, Qingming Zhang, Jianqing Zhu, Qunxian Rao, Huijun Cheng, Zheng Liu, Yongmei Yin, Xiaohong Ai, Kurban Gulina, Hong Zheng, Xiaoyong Luo, Baoping Chang, Li Li, Haiyan Liu, Yunxia Li, Ge Lou, Qi Zhou, Yanling Zhu, Zemin Xiao, Jiandong Tong, Ke Wang, Jie Chen, Xia W |
|---|---|
| YEAR | 2023 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 31 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |